Renzapride in IBS: is efficacy in the eye of the beholder?

  title={Renzapride in IBS: is efficacy in the eye of the beholder?},
  author={Annalise Caroline Ford},
  journal={Alimentary Pharmacology \& Therapeutics},
  • A. C. Ford
  • Published 1 July 2010
  • Medicine
  • Alimentary Pharmacology & Therapeutics
: 16 Oct 2005 - Added using 'Add Referee on the fly' by Prof. Walter L Peterson (Ford, Alexander) 
Renzapride in IBS: is efficacy in the eye of the beholder? author’s reply
This poster presents the results of a double-blind, randomized, placebo-controlled study on the treatment of women with irritable bowel syndrome and constipation with renzapride and a review of the literature on 5-HT3 antagonists and5-HT4 agonists and their applications in functional gastrointestinal disorders.
Assessment of Consensus-Based Pharmacological Therapies in Irritable Bowel Syndrome
There is a need for new drugs in the setting of pharmacological therapy for the IBS and a new medical approach should include both novel and traditional drugs in order to reach to a desirable outcome for patients and improve their quality of life.
Irritable Bowel Syndrome: a Review -
The available strategies and the future frontiers regarding IBS, ranging from diagnosis to treatment are discussed, to decrease the worldwide burden of this disease.


Clinical trial: lubiprostone in patients with constipation‐associated irritable bowel syndrome – results of two randomized, placebo‐controlled studies
This clinical trial aimed at determining the causative mechanism behind irritable bowel syndrome with constipation (IBS‐C) and its prognosis was successful in patients with symptomatic IBS-C.
Efficacy of 5-HT3 Antagonists and 5-HT4 Agonists in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis
A systematic review and meta-analysis of randomized controlled trials to estimate the efficacy of all available 5-HT agents in IBS found alosetron, cilansetrons, and tegaserod are all effective in the treatment of IBS.
Design of treatment trials for functional gastrointestinal disorders
Until recently many clinical trials of functional gastrointestinal disorders (FGIDs) suffered from important weaknesses in trial design, study execution, and data analysis. This makes it difficult to
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
This monograph was developed to educate physicians about its epidemiology, diagnostic approach, and treatments of Irritable Bowel Syndrome to critically evaluate the rapidly expanding research about IBS.
American College of Gastroenterology IBS Task Force. An evidence-based position statement on the management of irritable bowel syndrome
  • Am J Gastroenterol
  • 2009
Design of Treatment Trials
  • Gastroenterology
  • 2006